Biogen Reveals Deal with Ionis for Development of New Drug for SMA
05 January 2022
Biogen has announced that it has entered into an agreement with Ionis Pharmaceuticals to develop and commercialise a new antisense oligonucleotide for SMA.
Known as BIIB115, this investigational drug is reported to have the potential for longer intervals between treatments, and may help to address some of the unmet needs of patients. Biogen intends to assess the safety, tolerability, pharmacokinetics, and efficacy of BIIB115 in clinical trials.
It is currently unclear how BIIB115 works.
For further information, please see the press release from Biogen.